Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on interview and document review, the facility failed to implement a system to ensure appropriate follow up on wound culture results to prevent potential inappropriate use of antibiotics and determine whether to use special precautions for 1 of 1 resident (R1).
Findings include:
R1's annual Minimum Data Set (MDS) dated [DATE], indicated intact cognition, was dependent on staff for all activities of daily living (ADLs), had an indwelling catheter, was frequently incontinent of bowels, was at risk for pressure ulcers, and had a stage 4 pressure ulcer (A stage four pressure ulcer is full thickness loss of the skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage or bone in the ulcer. Slough and or eschar may be visible on some parts of the wound bed. Undermining and or tunneling often occur. If slough or eschar obscures the wound bed, it is an unstageable pressure ulcer).
R1's Medical Diagnosis form indicated the following diagnoses: multiple sclerosis, paraplegia, pressure ulcer of the sacral region stage 4, history of urinary tract infections, and functional quadriplegia.
R1's physician orders indicated the following orders and start dates:
•
3/20/24: daily monitoring of skin to coccyx pressure if any signs or symptoms of complications complete a progress note and update the physician or nurse practitioner (NP) as needed. Otherwise considered clean, dry and intact with no signs and symptoms of complications. Symptoms of infection: warm, red, purulent drainage, tender surrounding skin: indicate if macerated, denuded, erythematous, indurated. Drainage: indicate amount, color, and odor if not within normal limits.
•
3/20/24: infection: wound infection refer to the infection progress note template for assessment and documentation requirements. Document at least with the start and end of an antibiotic regimen and during the course of treatment with a clinical change or vital signs assessment that is not within normal limits.
•
3/13/24: Bactrim DS oral tablet 800-160 milligram (MG) sulfamethoxazole-trimethoprim (an antibiotic) give 1 tablet two times daily for wound infection for 10 days.
•
3/8/24: Coccyx (tailbone) wound care: apply Vashe (a wound cleanser that inhibits microbial contamination)-moistened gauze into wound bed for 10 minutes then remove and pat dry. Nystatin powder (an antifungal) over fungal rash and crust into place with skin prep. Apply two layers of Alginate AG Rope (A dressing used to absorb moderate to heavy amounts of wound exudate) dressing into the wound bed, cover with an occlusive foam dressing to prevent soiling from stool or urine.
R1's medication administration record (MAR) and treatment administration record (TAR) for March 2024, was reviewed and lacked information regarding following up on a wound culture report.
R1's care plan revised 6/23/23, indicated R1 was at risk for infection related to suprapubic catheter in place, pressure ulcer of coccyx, history of infections (Septic shock), cellulitis, strep bacteremia, COVID, and urinary tract (UTI). Interventions indicated change my dressing per orders, give the medication as ordered, monitor for signs and symptoms of illness, encourage fluids per facility policy, isolate per facility policy, review with the resident the risk versus benefits of his decisions, monitor for increased symptoms of infection which may include increased temperature, altered mental status or vital signs, increased drainage, lethargy or redness of site. Additionally, interventions indicated to monitor lab results per physician orders. R1's care plan lacked information R1 had a current wound infection.
R1's After Visit Summary note dated 3/7/24, in the electronic medical record (EMR) indicated R1 was seen at the wound clinic 3/7/24, and a wound culture was obtained.
R1's progress notes dated 3/1/24, indicated R1 had a stage 4 full thickness pressure ulcer and the note indicated the dressing was done and the wound bed had moderate drainage and was co-managed by the wound clinic.
R1's progress notes dated 3/7/24, indicated R1 had new orders from the wound clinic.
R1's progress notes were reviewed from 3/6/24, to 3/20/24, and lacked evidence a request for R1's culture and sensitivity report of the wound infection had been requested until 3/20/24, when a progress note was entered at 8:50 a.m., indicating staff requested the culture and sensitivity of the wound infection from the wound clinic.
R1's care sheet dated 3/15/24, indicated R1 required assist of two to reposition every two hours and as needed. The care sheet lacked information R1 had a current wound infection.
R1's medical records were reviewed and lacked information a culture and sensitivity for the wound culture was received by the facility.
The facilities antibiotic tracking log indicated R1 had a cellulitis/soft tissue/wound to skin and the infection according to the wound doctor was in the sacral pressure ulcer and the date of onset was 3/8/24. The log indicated R1 had a wound culture, however there was no follow up of the results from the culture documented and under the heading, transmission based precautions required indicated transmission based precautions were not required.
On 3/20/24 at 12:16 p.m., an emailed wound clinic progress note indicated R1 was seen at the clinic on 3/7/24, had subcutaneous wound debridement with a wound culture obtained by the NP, and the clinic would contact the facility if antibiotics were required. Additionally, the note indicated the sacral wound had moderate to large amount of serosanguinous drainage, and under instructions, indicated wound care orders with an occlusive foam dressing to prevent soiling from stool or urine. The urine had been bypassing the catheter.
On 3/20/24 at 1:15 p.m., an emailed wound culture and sensitivity report for R1 indicated the final results for the wound culture was dated on 3/10/24, and acknowledged by the nurse practitioner (NP) on 3/11/24. The clinic nurse contacted the facility on 3/13/24, to call in the prescription for Bactrim DS one table twice daily for 10 days. The wound culture indicated R1 had staphylococcus aureus and under the comment indicated the isolate was MRSA (methicillin resistant Staph aureus, a bacteria that is difficult to treat because of resistance to some antibiotics). Additionally, the wound culture indicated there was mixed flora present and Providencia rettgeri (a bacteria).
During interview on 3/18/24 at 12:32 p.m., the administrator stated the infection preventionist worked at a couple of campuses and would be on site at this facility on 3/19/24.
During interview on 3/18/24 at 1:20 p.m., R1 stated he was on an antibiotic for his wound and his wound was biopsied and his catheter had been leaking.
During interview on 3/19/24 at 12:35 p.m., the infection preventionist (IP) stated lab results were located under the Miscellaneous form in the electronic medical record (EMR). The IP stated if a resident went to the clinic and an antibiotic was ordered they sometimes asked for the culture and sensitivity report and stated they would call if a resident was on an antibiotic and the culture and sensitivity was not located in the chart and added the clinical coordinators were good at following up. IP further stated they tried to get the culture and sensitivity report back as soon as they are available and stated they would enter a progress note when the culture came in. IP further stated when asked how they made sure obtaining the culture and sensitivities didn't get missed that she was not the only staff person who checked for cultures and stated the clinical coordinators were also making sure to follow up on cultures and sensitivities.
During interview on 3/20/24 at 8:27 a.m., registered nurse (RN)-A stated they followed up on cultures by monitoring and reporting cultures to the nurse practitioner to make sure the sensitivities were in line with the antibiotic ordered and if they were not, they followed up with the provider for a change in medication. RN-A stated R1 had a culture completed at the wound clinic and verified they did not have the wound culture report at the facility. RN-A further stated R1 started on an antibiotic on 3/13/24, and stated sensitivities typically took three days for urine cultures to come back, and R1 went to the wound clinic on 3/7/24, and did not know how long it took for wound cultures to be finalized. RN-A stated she would have to follow up and get the culture and sensitivity. When asked about the process to make sure a culture and sensitivity didn't get missed, RN-A stated the IP tracked infections with a form that indicated check for sensitivities. RN-A further stated she was not able to answer who followed up with the sensitivities when the IP was only at the facility two days a week, and would have to look at the process. RN-A verified there was no documentation anyone followed up with the culture and sensitivity and would check on it today. RN-A further stated the wound clinic would be looking at their own sensitivity, however the nursing facility would be expected to look at the sensitivity as well.
During phone interview on 3/20/24 at 9:03 a.m., the IP stated R1 was on Bactrim for a wound infection and stated as far as she knew, R1 did not have a wound culture done. When asked how staff know to follow up if there was a culture, the IP stated the lab reported back and faxed information over and staff communicate there is a culture pending and to watch for it, but would have to pull the director of nursing into the conversation to know the steps on a day to day basis because the IP reviews notes and was not a fly on the wall for each shift.
During interview on 3/20/24, 9:24 a.m., the wound clinic provided an email for a request for medical records for R1's wound progress notes and culture results.
During interview on 3/20/24 at 1:56 p.m., NP-E stated she would defer any special precautions to the facilities infectious disease policy and further stated she did not order the wound culture and did not know if the two organisms required special precautions.
During interview on 3/20/24 at 2:07 p.m., the medical director (MD) stated he would advise not to complete a wound culture unless it was a tissue biopsy. MD further stated he thought it was the responsibility of the ordering provider to keep track of culture results especially if it was completed outside the facility and stated special precautions depended whether there was unprotected drainage from the wound and stated R1 was in his room all the time and if up, was confined to a wheelchair and stated standard precautions should be more than sufficient.
During interview on 3/20/24 at 2:23 p.m., the director of nursing (DON) stated the IP handled infection control and had an infection log that was provided. The DON stated once they have the culture and sensitivity report, it is faxed to the provider. If the NP or physician orders a culture, they collect it at the facility and send it to the lab and wait for the result. The staff can look and monitor the process and follow up on the result and stated for example if a urine culture (UC) was completed, the treatment administration record (TAR) would indicate a UC was collected and they had a paper tracking form in a lab book. The DON stated the wound clinic would send a wound culture. At 2:29 p.m., the DON grabbed a pathway lab book and clarified since R1 had a culture completed at the wound clinic, the culture would not be in the pathway lab book because this book was for in house only labs. DON further stated the medical director called and said standard precautions was fine for R1 because R1 did not leave the room. Now we will plan to do contact precautions and stated they put the cart in there already and stated in practice, they should follow up on the cultures, but was difficult to track when the clinics did the labs. DON further stated it was important to complete contact precautions in theory, but R1 had minimal risk.
A policy, Infection prevention and Control Antibiotic Stewardship and MDROs, dated 2020, indicated antibiotic stewardship refers to systematic efforts to optimize the use of antibiotics not just reduce the total volume used to maximize their benefits to patients, while minimizing both the rise of antibiotic resistance as well as adverse effects to patients from unnecessary antibiotic therapy. Stewardship involves identifying the microbe responsible for disease, utilizing evidence based definitions when indicated; selecting the appropriate antibiotic along with documentation indicating the rationale for use, appropriate dosing, route, and duration of antibiotic therapy; and to ensure discontinuation of antibiotics when they are no longer needed. CMS requires an antibiotic stewardship program as a condition of participation for Medicare and Medicaid programs. There are 7 core elements for antibiotic stewardship in nursing homes outlined by the Centers for Disease Control (CDC): leadership commitment, accountability, drug expertise, action, tracking, reporting, education. The IP will be responsible for surveillance, infection definition based on standards of practice, education, tracking, data management, analysis of data, communication with the DON, medical and consultant pharmacist and ongoing system review. Tracking and reporting of antibiotic use and outcomes will be completed in the facility to identify adherence to facility policy and procedures, use and outcomes. Tracking will allow the facility to identify patterns, prevalence of antibiotic use as well as specific ordering data. Outcomes (i.e. adverse drug events, antibiotic resistant organisms, C. Difficile infections, etc.) will be tracked by the infection preventionist and discussed with the quality assurance committee for action planning. If an antibiotic therapy is ordered, documentation will include diagnosis or indication, medication, dose, route, and duration. In the event that diagnostic testing had been ordered, prompt communication of results will be provided to the practitioner. Monitor review response to antibiotics, and laboratory results when available, to determine if the antibiotic is still indicated or adjustments should be made. Multi-drug resistant organisms (MDROs) pose a serious threat to the health and well-being of our nation. Facilities must develop an action plan to include outbreak response processes in place to prevent the spread of and reduce the dangerous outcomes of these multi drug resistant organisms or superbugs. MDROs found in facilities can include, but are not limited to MRSA, VRE, CRE, KPC, and Clostridium difficile. Transmission based precautions may be employed for residents who have actively infected with MDROs. Aggressive infection control measures and strict compliance by healthcare personnel can help minimize the spread of MDROs to other susceptible individuals. It is important for facilities to have good systems in place to keep residents safe.